Preliminary results from an open-label Phase 3 clinical trial, Study 20120215, evaluating Amgen’s (NASDAQ:AMGN) Blincyto (blinatumomab) compared to conventional consolidation chemo in pediatric patients with high-risk, B-cell acute lymphoblastic leukemia (ALL) at first relapse met the primary endpoint of event-free survival. Considering the positive outcome, enrollment has been terminated. No new safety signals were observed.
The data will be submitted for presentation at a future medical conference.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.